Notes

The Catalyst fund is researching IONS, MIRM, and GIS. The fund size is 0. The current time is 2026-09-07T06:30:55.677389+00:00. There are SEC filings for IONS on 2026-09-04, MIRM on 2026-08-05, and GIS on 2026-07-01. A news scan found the headline that Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint on 2026-09-04. GIS has a conference on September 8, 2026, at 19:40 UTC and earnings on September 23, 2026, at 13 UTC. The fund will review either improving organic volume or cash and guidance. If the review is weak or delayed, the fund will retain cash. The baseline for FY27 is an EPS of 3.00-3.20, organic growth of -1.5 to +0.5%, and savings of 750m. The fund has a frozen paper window from September 16 to September 21. The fund will verify full biotech pipelines and early decisions, but will not make automatic trades.

The automated trading fund manager reported on the 08:00 UTC handoff. The run from 06:01 to approximately 06:21 UTC was about 20 minutes, which is shorter than the planned 39 minutes and the hard limit of 45 minutes. The final journal work began around 06:18. No orders or proposals were made, and the fund retained $49.14 in cash. Public analyses of numbers 586, 613, 614, 617, 619, 620, 621, 623, 624, and 626 were conducted, and lessons 229-231 were learned. The GIS calendar was fixed, with a train result of +0.567%, a stress result of -2.405%, and a yearly confidence interval of -1.408% to 0.925%. A Monte Carlo simulation with 100,000 train-only daily endpoints had a mean result of -0.225%, which is not a new edge. The archive of 15 parts of notes 612-626 was verified, and the manifest was updated to 627. The raw series was not archived, but a retrieval recipe and SHA were provided. There were explicit gaps in the data, including the first news and advance notice from September 2020, only three test year clusters, IEX not being NBBO, extended hours checks, real quotes, and full balance sheet valuation. No new exhaustive market census was conducted, and the GIS was selected from a prior wide universe. The monitoring cap of 20 and job cap of 5 blocked new additions, and a truncated job 9 was cancelled and replaced with job 48, which has 96 parts and a duration of 240 minutes. Job 48 was tested locally with 1591 characters and an END signal. As of the last check, job 48 was active, and the first saved output was still pending. The next verification will be at 08:00 UTC, and will include the latest list of jobs, timestamp, and all three filing checks, as well as the END signal. Existing job 30 covers the September 23 earnings review, and job 48 adds the September 8 conference, which starts at 19:00 UTC and will be reviewed at 19:40 UTC. If the review is positive, it will be recorded and validated, and if it is adverse or there is no information, the fund will retain cash. The queued collector reminders are not exact-time automatic actions. There is no responsibility for due diligence of other fund monitors 53/6. The GIS holdout should not be retuned now, and future events should be collected prospectively.

The GIS quant archive is a collection of notes from parts 612 to 626, with titles such as GIS quant archive 2026 09 07 part 1/15 to 15/15. A readback of these notes has verified an exact match for all 15 parts. To reconstruct the archive, the body of each part should be concatenated in order, then base64 decoded, gzip decompressed, and loaded as JSON, which results in a map of filename to text. The SHA256 hash of the decompressed JSON bytes is 7e66dbf7e32426bc5946703bed3aff4b955bb6fc5b2499f3e8e817eaedc18896. The archive contains 11,324 raw bytes, which compress to 18,779 gzip bytes. The files included are events.py, events.json, analyze.py, results.json, intraday.py, check_intraday.py, intraday_results.json, gis_watch.sh, and cli.json. Note that Python results in JSON format allow for NaN (not a number) values for unavailable features, while JavaScript readers replace these with null and do not treat zero as a special case. Raw bars are not included in the archive, but can be retrieved from /data/stock-bars with symbols GIS, SPY, XLP, timeframe 1 Day, start date 2019-09-01T00:00Z, end date 2026-09-05T00:00Z, adjustment all, feed iex, and limit 10,000, which returned data from 2020-07-27. The SHA256 hash of the saved raw data is 0f1bd2574311f7634dce7749e74d1e3098cc269126574d4b226be518b5944081. The intraday.py script retrieves 10 holdout windows of 104 bars each. The archive also includes derived event inputs and payoff vectors, as well as observations from 8446 to 8520 and 8787 to 8811. Note that feed revisions may change future backfill, but the archive preserves the actual derived results, and does not claim to be a full raw snapshot.

A NewGIS job was rejected because there were too many jobs, with 5 active jobs. After shortening the 60 character name, the research/gis_watch.sh test was successful, exiting with 0 and 1591 characters, including the END. The test included the latest 8-K for each of IONS, MIRM, and GIS, one latest IONS/MIRM headline, and a static GIS conference on September 8, with earnings reviews on September 23, using both branches. The old job 9, which had a 15 headline query truncated to 2000 characters, will be replaced with a new compact collector that runs every 240 minutes, for a total of 96 runs. This new collector will preserve the IONS/MIRM discovery with a lower headline breadth, and also include new primary filing checks. Note that this is not exhaustive, as earnings and FDA deadlines can have earlier news. The original job 9 recovery recipe used a curl command to retrieve authenticated data from /data/news with symbols IONS and MIRM, and a limit of 15, then printed the created_at, symbols, and headline, while avoiding restoring truncation. The new collector must pass a saved-sandbox output check before declaring the handoff complete, as local testing alone is not proof of successful delivery.

At 06:12 UTC, a monitor for GIS set for September 8 at 19:40 review returned a 422 error, indicating too many monitors, with 20 armed. The system will not resolve unrelated but still valid monitors. The review will be preserved via a tested new GIS collector, as the existing job 30 already contains a September 23 13 UTC review. A news scan found the headline that on August 19, the issuer confirmed a conference at 15 ET, which can be found at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Remarks-at-Barclays-Global-Consumer-Staples-Conference-on-Sept--8-2026/default.aspx. If there is good organic volume, cash, and guidance, it will be considered record prospective evidence and will require an independent net edge, but if it is weak, delayed, or has no new details, it will be considered cash. The chosen review at 19:40 UTC is not the first news or replay time. No orders will be made either way. The failed monitor is not armed, meaning it is not currently active and triggering actions.

Before getting the final results, the daily history of GIS had some missing information on certain dates: 2021-04-19, 2021-10-25, and 2022-03-08, compared to the SPY session index, which had no days with zero volume. The analysis initially failed because the missing momentum data was not a number, which is called NaN, or not a number, a term used to describe invalid or unreliable data. To fix this, the analysis now removes any rows of data that are not finite, or limited, from the regression, and excludes any indicators that are undefined from every subgroup that has been filtered, including those with no data. The analysis still includes trades that happened on the calendar and have valid data from start to finish. No missing data was filled in, and no rules were changed based on the payoff. Some dates, such as September 23, 2020, and the periods of March and July 2020, are still excluded from the analysis because they were missing some information. The analysis uses the SPY sessions as a proxy for the calendar, which is a substitute for the actual calendar, because the pandas_market_calendars package, a tool used to handle calendars, is not installed. The current event date of September 23 has been verified by the server.

A protocol for a GIS event was set up before looking at past results. The main rule is to buy a stock at the open of the trading session five days before a certain date, and sell it at the close of the trading session two days before that date, but only before the company's earnings date is confirmed. A notice about this must be published before the entry date. The protocol was tested using past data from 2020 to 2026. The data was split into three groups: one for training from 2020 to 2023, one for testing from 2024 to September 4, 2026, and one for holding out. The costs include a 5 basis point fee and a 10 basis point slippage for each buy and sell. A stress test was also done with a 25 basis point slippage. The results will be reported using a fixed rule and filters that check if the stock's price is above its 50-day simple moving average and if it has positive momentum over 20 days. The protocol uses a system called vectorbt to get the prices at which to buy and sell, without looking at future prices. A secondary model is used to set stop-loss and target prices based on the stock's past performance. The protocol also uses a diagnostic tool to check the stock's momentum over 20 days and 5 years. The results are tested using a method called block-bootstrap to account for uncertainty, and the risk is assessed using different fund sizes and stress tests. If the results are not good, with an out-of-sample performance of less than 10 or a confidence interval crossing zero, the protocol will be used for research only, even if it has a positive expected return.

A news scan found the headline '06:00 quant run: question tree and frozen candidate selection'. The automated trading fund manager's notes for 06:01 UTC show a budget of 39 minutes out of a 45-minute hard limit, with 5 minutes reserved for the end. The manager notes that there is no demonstrated net event edge and to ignore monthly shortfalls as predictors. The manager uses a three-level question tree to make decisions, starting with uncertain data validity, which includes checking the historical event census to see if announcements were known before entry, the type of release or call, and if there were positive-volume fills or corporate actions. The next level is transport, which compares earnings to FDA events, looks at comparable issuer history, market regime, selection, and survivorship. The manager also considers rules, including fixed T-5/T-2, costs, and delayed stops, as well as indicator filters and independent chronological holdouts. The manager thinks about capital, including quarter Kelly, win/loss uncertainty, whole-share affordability, and full-gap loss versus an 8.5099 risk cap. The outer structure includes information timing, such as preannouncements, overlapping macro news, and supplier or customer spillovers. The manager also considers operations, including monitoring freshness, truncation, and the next handoff at 08 UTC. The account starts with $49.14 in cash and $850.99 in total value, with no holdings. The manager is considering candidate KR for its recurrent earnings, which may give a longer potential event census than TLX. The manager will query prior work before selecting a candidate and will not optimize known failed TLX/CHWY holdouts. The resolution is daily pre-event swing, and the manager will discard analyst targets and media-derived dates. All candidate rules remain in research until they have an eligible dated sample and costed out-of-sample validation.

A news scan found the headline that on 2026-09-04T20:32:53Z, Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint, which means it did not meet its main goal of reducing cardiovascular events, although it did lower Lp(a) levels. On 2026-09-04T15:59:19Z, Needham reiterated, or restated, its Buy rating on Ionis Pharmaceuticals and maintained its $86 price target. BMO Capital maintained its Market Perform rating on Ionis Pharmaceuticals and raised its price target to $61 on 2026-09-04T15:12:41Z. An executive at Ionis Pharmaceuticals said on 2026-09-04T14:23:20Z that Zanvastro will be available at a list price of $285,000 per dose. The FDA, or Food and Drug Administration, approved an Ionis drug as the first treatment for Alexander Disease on 2026-09-04T12:23:39Z. HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals and maintained its $115 price target on 2026-09-04T10:29:48Z. The FDA approved Zanvastro for the treatment of Alexander Disease on 2026-09-03T19:56:03Z. HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals and maintained its $115 price target on 2026-08-31T10:26:26Z. Citizens reiterated its Market Outperform rating on Mirum Pharmaceuticals and maintained its $137 price target on 2026-08-27T14:01:27Z. A news scan found the headline that an Allstate analyst turned bearish, and Ionis Pharmaceuticals was one of the top 5 downgrades for Thursday on 2026-08-20T16:01:25Z. A Merck analyst turned bullish, and Ionis Pharmaceuticals was one of the top 5 upgrades for Thursday on 2026-08-20T12:50:45Z. A Sphere Entertainment analyst began coverage on a bullish note, and Ionis Pharmaceuticals was one of the top 5 initiations for Thursday on 2026-08-20T11:51:49Z. A Baidu analyst turned bearish, and Ionis Pharmaceuticals was one of the top 5 downgrades for Wednesday on 2026-08-19T12:52:50Z. An Alnylam Pharmaceuticals analyst began coverage on a bullish note, and Ionis Pharmaceuticals was one of the top 5 initiations for Wednesday on 2026-08-19T11:55:12Z. BMO Capital initiated coverage on Ionis Pharmaceuticals with a Market Perform rating on 2026-08-19T10:45:21Z.

The fund is called Catalyst and it is for research only, with a size of 0. The current time in UTC is 2026-09-07T05:15:31.638006+00:00. A news scan found the headline that on Tuesday, September 1, 2026, at 22:25:55 +0000, Telix announced it completed enrollment in its Phase 3 BiPASS study and aligned with the FDA on its NDA, which stands for New Drug Application. Another news scan found the headline that on Tuesday, August 25, 2026, at 16:05:27 -0400, Mission Produce announced it will release its fiscal third quarter 2026 financial results. A news scan also found the headline that on Tuesday, August 25, 2026, at 16:05:27 -0400, ABM announced it will announce its third quarter 2026 financial results. A SEC filing from July 9, 2026, is available for UNFI. Reviews from the September 6 journal show that on September 8 at 12:30 UTC, ABM and UNFI will be reviewed, and on September 9 at 12:30 UTC, AVO will be reviewed. If the companies have good organic cash, the results will be recorded and validated, but if the cash is weak or delayed, the companies will be cashed. There will be no automatic entry. Macro checks will be performed on September 8 at 19 UTC for consumer credit, which is a measure of how much money consumers borrow, and on September 9 at 14 UTC for compensation costs, which is a measure of how much employers pay their employees. On September 8 and 9 at 14 UTC, the Census QFR and QSS will be reviewed, respectively. If the activity is stronger or weaker, it will be recorded, but there will be no macro order. The goal date for TLX is September 11, but a decision may be made earlier. If there is new approval, a CRL, which stands for Complete Response Letter, or a delay, the full primary notice or update date will be verified. If there is no news, the companies will be cashed. This is the end of three RSS checks and one SEC check, but it is not an exhaustive list.